76 related articles for article (PubMed ID: 14724428)
1. Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen.
Aramaki O; Shirasugi N; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Azuma M; Okumura K; Yagita H; Niimi M
Transplantation; 2004 Jan; 77(1):6-12. PubMed ID: 14724428
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
3. Various costimulatory pathways are essential for induction of regulatory cells by intratracheal delivery of alloantigen.
Aramaki O; Inoue F; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Okumura K; Yagita H; Shirasugi N; Niimi M
Transplant Proc; 2005 May; 37(4):1934-6. PubMed ID: 15919509
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
Wang L; Han R; Hancock WW
Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
[TBL] [Abstract][Full Text] [Related]
5. CD27/CD70, CD134/CD134 ligand, and CD30/CD153 pathways are independently essential for generation of regulatory cells after intratracheal delivery of alloantigen.
Aramaki O; Shirasugi N; Akiyama Y; Shibutani S; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Okumura K; Yagita H; Niimi M
Transplantation; 2003 Sep; 76(5):772-6. PubMed ID: 14501851
[TBL] [Abstract][Full Text] [Related]
6. Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts.
Koga N; Suzuki J; Kosuge H; Haraguchi G; Onai Y; Futamatsu H; Maejima Y; Gotoh R; Saiki H; Tsushima F; Azuma M; Isobe M
Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2057-62. PubMed ID: 15374847
[TBL] [Abstract][Full Text] [Related]
7. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y; Wood CR; Chernova T; Chaudhary D; Borde M; Chernova I; Iwai Y; Long AJ; Brown JA; Nunes R; Greenfield EA; Bourque K; Boussiotis VA; Carter LL; Carreno BM; Malenkovich N; Nishimura H; Okazaki T; Honjo T; Sharpe AH; Freeman GJ
Nat Immunol; 2001 Mar; 2(3):261-8. PubMed ID: 11224527
[TBL] [Abstract][Full Text] [Related]
8. Induction of operational tolerance and generation of regulatory cells after intratracheal delivery of alloantigen combined with nondepleting anti-CD4 monoclonal antibody.
Aramaki O; Shirasugi N; Akiyama Y; Takayama T; Shimazu M; Kitajima M; Ikeda Y; Niimi M
Transplantation; 2003 Nov; 76(9):1305-14. PubMed ID: 14627908
[TBL] [Abstract][Full Text] [Related]
9. Induction of indefinite survival of fully allogeneic cardiac grafts and generation of regulatory cells by intratracheal delivery of alloantigens under blockade of the CD40 pathway.
Uchida N; Shirasugi N; Akiyama Y; Matsumoto K; Shimazu M; Kitajima M; Hamano K; Aramaki O; Ikeda Y; Niimi M
Transplantation; 2003 Mar; 75(6):878-84. PubMed ID: 12660518
[TBL] [Abstract][Full Text] [Related]
10. Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.
Cao J; Liu FX; Yu MX
Chin Med J (Engl); 2009 Aug; 122(16):1941-6. PubMed ID: 19781375
[TBL] [Abstract][Full Text] [Related]
11. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.
Meng Q; Yang P; Li B; Zhou H; Huang X; Zhu L; Ren Y; Kijlstra A
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4444-52. PubMed ID: 17003438
[TBL] [Abstract][Full Text] [Related]
12. Deletion of alloantigen-reactive thymocytes as a mechanism of adult tolerance induction following intrathymic antigen administration.
Jones ND; Fluck NC; Roelen DL; Mellor AL; Morris PJ; Wood KJ
Eur J Immunol; 1997 Jul; 27(7):1591-600. PubMed ID: 9247566
[TBL] [Abstract][Full Text] [Related]
13. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.
Terrazas LI; Montero D; Terrazas CA; Reyes JL; RodrÃguez-Sosa M
Int J Parasitol; 2005 Nov; 35(13):1349-58. PubMed ID: 16126211
[TBL] [Abstract][Full Text] [Related]
14. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Iwai Y; Ishida M; Tanaka Y; Okazaki T; Honjo T; Minato N
Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12293-7. PubMed ID: 12218188
[TBL] [Abstract][Full Text] [Related]
15. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
16. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Blank C; Gajewski TF; Mackensen A
Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
[TBL] [Abstract][Full Text] [Related]
17. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
Raptopoulou AP; Bertsias G; Makrygiannakis D; Verginis P; Kritikos I; Tzardi M; Klareskog L; Catrina AI; Sidiropoulos P; Boumpas DT
Arthritis Rheum; 2010 Jul; 62(7):1870-80. PubMed ID: 20506224
[TBL] [Abstract][Full Text] [Related]
18. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of NIT-1 cells expressing pD-L1 for treatment of streptozotocin-induced diabetes.
Wen X; Zhu H; Li L; Li Y; Wang M; Liu J; Yang D; Liao W; Shen G
Transplantation; 2008 Dec; 86(11):1596-602. PubMed ID: 19077895
[TBL] [Abstract][Full Text] [Related]
20. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells.
Gorczynski L; Chen Z; Hu J; Kai Y; Lei J; Ramakrishna V; Gorczynski RM
J Immunol; 1999 Jan; 162(2):774-81. PubMed ID: 9916698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
